Ecallantide

Drug Profile

Ecallantide

Alternative Names: CB-500,929; DX-88; EPI-KAL2; FOV 2302; Kalbitor

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Dyax
  • Developer Cubist Pharmaceuticals; Dyax; Fovea Pharmaceuticals; Neopharm Ltd; Shire
  • Class Peptides; Recombinant proteins
  • Mechanism of Action Plasma-kallikrein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hereditary angioedema
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hereditary angioedema
  • Suspended Retinal oedema
  • Discontinued Angioedema; Surgical blood loss

Most Recent Events

  • 22 Jan 2016 Dyax has been acquired by and merged into Shire
  • 21 Jan 2015 Cubist Pharmaceuticals has been acquired by Merck & Co
  • 01 Jun 2014 CMIC terminates its licence for ecallantide in Japan (Dyax 10-K, February 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top